The miR27b-CCNG1-P53-miR-508-5p axis regulates multidrug resistance of gastric cancer

Oncotarget

Volumn 7, Issue 1, 2016, Pages 538-549

  Shang, Yulong ^a   Feng, Bin ^a   Zhou, Lin ^b   Ren, Gui ^a   Zhang, Zhiyong ^a   Fan, Xing ^a   Sun, Yi ^c   Luo, Guanhong ^a   Liang, Jie ^a   Wu, Kaichun ^a   Nie, Yongzhan ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b 88th Hospital of PLA   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CCNG1; Gastric cancer; MiR 27b; MiR 508 5p; Multidrug resistance

Indexed keywords

CYCLIN G1; MICRORNA; MICRORNA 27B; MICRORNA 508 5P; PROTEIN P53; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; CCNG1 PROTEIN, HUMAN; CISPLATIN; FLUOROURACIL; MIRN27 MICRORNA, HUMAN; MIRN508 MICRORNA, HUMAN; VINCRISTINE;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DISEASE MARKER; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN STABILITY; REGULATORY MECHANISM; STOMACH CANCER; UPREGULATION; ANIMAL; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; METABOLISM; MIDDLE AGED; NUDE MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; CYCLIN G1; DRUG RESISTANCE, MULTIPLE; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MICE, NUDE; MICRORNAS; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84979704466     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/ONCOTARGET.6374     Document Type: Article

References (31)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5-29
2. Fodale V, Pierobon M, Liotta L, Petricoin E. Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J. 2011;17:89-95
3. Noguchi K, Katayama K, Sugimoto Y. Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. Pharmgenomics Pers Med. 2014; 7:53-64
4. Yu J, Gao J, Lu Z, Gong J, Li Y, Dong B, Li Z, Zhang X, Shen L. Combination of microtubule associated protein-tau and β-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer. Eur J Cancer. 2014;50:2328-2335
5. Elkholi R, Renault TT, Serasinghe MN, Chipuk JE. Putting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy? Cancer Metab. 2014; 2:16
6. Pflaum J, Schlosser S, Müller M. p53 Family and Cellular Stress Responses in Cancer. Front Oncol. 2014; 4:285
7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297
8. Shang Y, Zhang Z, Liu Z, Feng B, Ren G, Li K, Zhou L, Sun Y, Li M, Zhou J, An Y, Wu K, Nie Y, Fan D. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene. 2014; 33:3267-3276
9. Kwon SH, Park JC, Ramachandran S, Cha SD, Kwon KY, Park JK, Park JW, Bae I, Cho CH. Loss of cyclin g1 expression in human uterine leiomyoma cells induces apoptosis. Reprod Sci. 2008;15:400-410
10. Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O, Choi IJ, Munroe DJ, Green JE. miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics. 2011; 4:79
11. Huang D, Wang H, Liu R, Li H, Ge S, Bai M, Deng T, Yao G, Ba Y. miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer. J Cell Biochem. 2014;115:549-556
12. Chen Z, Zhang L, Xia L, Jin Y, Wu Q, Guo H, Shang X, Dou J, Wu K, Nie Y, Fan D. Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. Cancer Lett.2014;350:43-51
13. Zhang Y, Qu X, Li C, Fan Y, Che X, Wang X, Cai Y, Hu X, Liu Y. miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1. Tumour Biol. 2015;36:2277-2285
14. Zhao X, Liu M, Li D. Oleanolic acid suppresses the proliferation of lung carcinoma cells by miR-122/Cyclin G1/MEF2D axis. Mol Cell Biochem. 2015; 400:1-7
15. Selcuklu SD, Donoghue MT, Rehmet K, de Souza Gomes M, Fort A, Kovvuru P, Muniyappa MK, Kerin MJ, Enright AJ, Spillane C. MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. J Biol Chem. 2012; 287:29516-29528
16. Wen W, Han T, Chen C, Huang L, Sun W, Wang X, Chen SZ, Xiang DM, Tang L, Cao D, Feng GS, Wu MC, Ding J et al. Cyclin G1 expands liver tumor-initiating cells by Sox2 induction via Akt/mTOR signalling. Mol Cancer Ther. 2013; 12:1796-1804
17. Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z, Liu J, Cui Y, Bian X, Bie P, Qian C. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett. 2011; 310:160-169
18. Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, Chieco P, Negrini M, Bolondi L. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2009; 69:5761-5767
19. Kimura SH, Ikawa M, Ito A, Okabe M, Nojima H. Cyclin G1 is involved in G2/M arrest in response to DNA damage and in growth control after damage recovery. Oncogene. 2001; 20:3290-3300
20. Okamoto K, Li H, Jensen MR, Zhang T, Taya Y, Thorgeirsson SS, Prives C. Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol Cell. 2002;9:761-771
21. Ohtsuka T, Ryu H, Minamishima YA, Ryo A, Lee SW. Modulation of p53 and p73 levels by cyclin G: implication of a negative feedback regulation. Oncogene 2003;22:1678-1687
22. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer. 2012;12:613-626
23. Li Q, Zhang H, Tan C, Peng W, Ren G, Jia B, He Y, Wang P, Zhou X, Xiang T. AdHu5-apoptin induces G2/M arrest and apoptosis in p53-mutated human gastric cancer SGC-7901 cells. Tumour Biol. 2013; 34:3569-3577
24. Zhang L, Jia G, Li WM, Guo RF, Cui JT, Yang L, Lu YY. Alteration of the ATM gene occurs in gastric cancer cell lines and primary tumors associated with cellular response to DNA damage. Mutat Res. 2004;557:41-51
25. Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25:304-317
26. Jiang J, Lv X, Fan L, Huang G, Zhan Y, Wang M, Lu H. MicroRNA-27b suppresses growth and invasion of NSCLC cells by targeting Sp1. Tumour Biol 2014;35:10019-10023
27. Wan L, Zhang L, Fan K, Wang J. MiR-27b targets LIMK1 to inhibit growth and invasion of NSCLC cells. Mol Cell Biochem. 2014;390:85-91
28. Ye J, Wu X, Wu D, Wu P, Ni C, Zhang Z, Chen Z, Qiu F, Xu J, Huang J. miRNA-27b targets vascular endothelial growth factor C to inhibit tumor progression and angiogenesis in colorectal cancer. PLoS One. 2013;8:e60687
29. Zhuo L, Liu J, Wang B, Gao M, Huang A. Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep. 2013;29:555-562
30. Mu W, Hu C, Zhang H, Qu Z, Cen J, Qiu Z, Li C, Ren H, Li Y, He X, Shi X, Hui L1. miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res. 2015;25:477-495
31. Zhao X, He L, Li T, Lu Y, Miao Y, Liang S, Guo H, Bai M, Xie H, Luo G, Zhou L, Shen G, Guo C et al. SRF expedites metastasis and modulates the epithelial to mesenchymal transition by regulating miR-199a-5p expression in human gastric cancer. Cell Death Differ. 2014;21:1900-1913